BiPar Sciences Expands Clinical Development Of BSI-201, A N

**Curis helping to treat cancer, neurological degenerative, kidney disorders, CUDC-101. Pathways, hedgehog, EGFR, Her2, Hsp90, Bcr-Abl/Src, CDK, BCL, MEK, VEGF, HDAC.**

Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Clinical Trials News
Reply to topic
BiPar Sciences Expands Clinical Development Of BSI-201, A N
RSS FEED


Joined: 05 Apr 2006
Posts: 19275
Post Posted: Thu May 29, 2008 7:12 pm Reply with quote
BiPar Sciences, Inc. announced it has expanded its clinical trials program through the initiation of an additional Phase 2 study of its lead product candidate BSI-201. The trial will assess BSI-201, the first ADP-ribose polymerase (PARP) inhibitor in the company's DNA repair portfolio, for the treatment of uterine carcinosarcoma or malignant mixed mullerian tumors.

Read more...
View user's profileSend private message
BiPar Sciences Expands Clinical Development Of BSI-201, A N
All times are GMT - 7 Hours  
Page 1 of 1  
  
  
Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Clinical Trials News
 Reply to topic  
Forum Map
Site Map